257
Participants
Start Date
August 1, 2011
Primary Completion Date
February 3, 2022
Study Completion Date
February 3, 2022
Brivaracetam (BRV)
The max BRV dose will be 5.0 mg/kg/day, not to exceed a dose of 200 mg/day for subjects with body weight \>40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights \>50kg) is reached.
N01266 252, New York
N01266 105, Buffalo
N01266 104, Rochester
N01266 114, Pittsburgh
N01266 237, Durham
N01266 108, Gulf Breeze
N01266 103, Wellington
N01266 111, Columbus
N01266 107, Cincinnati
N01266 101, Saint Paul
N01266 118, Chicago
N01266 113, Chesterfield
N01266 117, Houston
N01266 243, Los Angeles
N01266 106, Boston
N01266 202, Brussels
N01266 203, Brussels
N01266 201, Leuven
N01266 204, Leuven
N01266 502, Hradec Králové
N01266 504, Ostrava Prouba
N01266 240, Prague
N01266 207, Lille
N01266 206, Paris
N01266 218, Bayern
N01266 209, Freiburg im Breisgau
N01266 210, Budapest
N01266 224, Budapest
N01266 247, Budapest
N01266 222, Debrecen
N01266 232, Miskolc
N01266 211, Cork
N01266 212, Messina
N01266 213, Parma
N01266 238, Pavia
N01266 239, Pavia
N01266 230, Roma
N01266 256, Roma
N01266 223, Aguascalientes
N01266 611, Chihuahua City
N01266 609, Culiacán
N01266 603, Guadalajara
N01266 610, Monterrey
N01266 404, Bialystok
N01266 403, Gdansk
N01266 406, Kielce
N01266 402, Krakow
N01266 401, Poznan
N01266 407, Szczecin
N01266 405, Wroclaw
N01266 309, Barcelona
N01266 306, Madrid
N01266 301, Palma de Mallorca
N01266 248, Seville
N01266 308, Valencia
N01266 215, London
UCB Pharma SA
INDUSTRY